Sabin IPV Vaccine Description 2022
Sabin Inactivated Poliovirus Vaccine (sIPV) is a liquid trivalent vaccine produced from Sabin poliovirus type 1, 2, and 3 strains grown on Vero cells. The sIPV, the Poliomyelitis Vaccine (Vero Cell), inactivated, Sabin strains, was prequalified by the World Health Organization in June 2022. The sIPV is available for United Nations agencies to purchase to support the global polio endgame strategy.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company (NASDAQ: SVA) that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
Sabin IPV Vaccine Indication
The Sabin IPV vaccine is indicated to prevent the Wild Polio Virus in the hope of completely eradicating the disease.
Sabin IPV Vaccine Dosage
The vaccine is administered as three intramuscular injections of (0.5ml) on Day 0, Day 30, and Day 60, respectively, and a single intramuscular injection of vaccine (0.5 ml) at 18 months.
Sabin IPV Vaccine News
December 29, 2022 - Sinovac Biotech Ltd. sales of non-pandemic vaccines increased 37% from $128 million to $ 176 million on broad-based growth.
June 2, 2022 - SINOVAC Biotech Ltd. announced that it received WHO prequalification for its Poliomyelitis Vaccine.
May 13, 2022 - A polio vaccination campaign is scheduled to run over three days using the bivalent oral polio vaccine (bOPV) throughout Bethlehem and Jerusalem.
July 19, 2021 - SINOVAC Biotech Ltd. announced it received a drug registration approval from the National Medical Product Administration of China for its Sabin strain-based inactivated polio vaccine (Vero cells) ("sIPV") on July 12, 2021. The vaccine is expected to be available on the market by the end of 2021. SINOVAC also submitted an application for prequalification to the WHO in early 2020, and the WHO conducted its on-site inspection in February 2021.
April 15, 2021 - The Lancet published - Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial. This study offers evidence that two doses of sIPV administered at 4 and 8–11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis.
February 19, 2021 - The twenty-seventh WHO meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 1 February 2021 with committee members and advisers attending via video conference, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine-derived polioviruses (cVDPV).
January 7, 2021 - South Korean-based biotechnology company announced that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ is the first to receive the World Health Organization prequalification be supplied globally.
September 1, 2019 - The sIPV is non-inferior compared with IPV. Both demonstrate a good safety profile.
April 8, 2019 - The results of this study were published in The Journal for Infectious Diseases. This analysis revealed that the studied sIPV demonstrated an immunogenicity profile non-inferior to that of the conventional IPV and a good safety profile.
Sabin IPV Vaccine Clinical Trials
The Sabin IPV Vaccine has been tested in over 38 clinical trials over the years.
